Jan Ping partners with Amgen, ONS, for cancer education

Share this article:
Jan Ping
Jan Ping

Celebrity make-up artist and cancer survivor Jan Ping has partnered with Amgen and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), for an educational campaign titled “Coping with Cancer From the Outside In.”

The campaign is focused on educating oncology nurses about skin-related side effects associated with epidermal growth factor receptor (EGFR) inhibitors, used to treat several kinds of cancer. The initiative launched April 30 at the annual ONS Congress in San Antonio, Texas, according to a company statement.

EGFR inhibitor therapy causes skin rash in up to 90% of patients, ranging from mild to potentially life-threatening skin rash. Additionally, the therapy can affect nails and cause skin cracking and hair disorders, sometimes exacting an emotional toll on patients. The Coping with Cancer campaign hopes to educate nurses about these side effects, and provide tips for patients to help them look their best during treatment, the statement said.

Amgen provided funding for a Nursing Handbook (here, in pdf), and markets Vectibix, an EGFR inhibitor. Jan Ping is an Emmy Award-winning make-up artist diagnosed with breast cancer and has dealt with physical appearance changes as a result. “I'm excited to be taking part in an important program that provides nurses with everyday tips they can teach patients to boost confidence during a difficult time,” said Ping in the release.

Other local training seminars are scheduled for New York City, Los Angeles and Miami during the second half of this year, according to the ONSEdge website: www.onsedge.com.   

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...